Signaturefd LLC Grows Position in AstraZeneca PLC (NASDAQ:AZN)

Signaturefd LLC boosted its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 3.6% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 59,243 shares of the company’s stock after acquiring an additional 2,045 shares during the quarter. Signaturefd LLC’s holdings in AstraZeneca were worth $4,616,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of AZN. TD Asset Management Inc grew its stake in shares of AstraZeneca by 8.6% in the 1st quarter. TD Asset Management Inc now owns 1,537,410 shares of the company’s stock valued at $104,160,000 after purchasing an additional 121,876 shares during the last quarter. Northcape Wealth Management LLC purchased a new stake in shares of AstraZeneca in the second quarter valued at $269,000. Wealthcare Advisory Partners LLC lifted its position in AstraZeneca by 9.7% during the first quarter. Wealthcare Advisory Partners LLC now owns 6,136 shares of the company’s stock worth $416,000 after buying an additional 543 shares during the period. Cetera Advisors LLC lifted its position in AstraZeneca by 124.5% during the first quarter. Cetera Advisors LLC now owns 98,262 shares of the company’s stock worth $6,657,000 after buying an additional 54,488 shares during the period. Finally, Diversify Advisory Services LLC acquired a new stake in AstraZeneca during the first quarter worth about $836,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Ratings Changes

AZN has been the topic of a number of research analyst reports. Barclays raised AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. Citigroup upgraded AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft cut AstraZeneca from a “hold” rating to a “sell” rating in a research report on Friday, September 13th. Finally, TD Cowen lifted their price objective on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, AstraZeneca presently has a consensus rating of “Moderate Buy” and an average price target of $89.75.

AstraZeneca Trading Down 0.5 %

Shares of NASDAQ:AZN traded down $0.36 during mid-day trading on Tuesday, reaching $77.08. 976,850 shares of the company’s stock were exchanged, compared to its average volume of 5,036,402. The firm has a market capitalization of $238.99 billion, a price-to-earnings ratio of 37.96, a PEG ratio of 1.45 and a beta of 0.46. The business’s fifty day moving average price is $81.03 and its 200-day moving average price is $78.35. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $87.68.

AstraZeneca (NASDAQ:AZN) last posted its earnings results on Thursday, July 25th. The company reported $0.99 earnings per share for the quarter, topping analysts’ consensus estimates of $0.98 by $0.01. The company had revenue of $12.45 billion for the quarter, compared to analyst estimates of $12.62 billion. AstraZeneca had a net margin of 13.11% and a return on equity of 29.34%. The firm’s revenue was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.08 EPS. On average, research analysts predict that AstraZeneca PLC will post 4.07 EPS for the current fiscal year.

AstraZeneca Cuts Dividend

The business also recently disclosed a Semi-Annual dividend, which was paid on Monday, September 9th. Stockholders of record on Friday, August 9th were given a dividend of $0.49 per share. This represents a dividend yield of 1.8%. The ex-dividend date of this dividend was Friday, August 9th. AstraZeneca’s dividend payout ratio (DPR) is currently 48.04%.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.